Overview

• Laboratory analysis confirmed the supplement contained sildenafil in doses sufficient to alter physiological functions.
• The presence of an active pharmaceutical ingredient legally reclassifies the product as a medicinal product requiring prior approval.
• AEMPS has prohibited further sales and instructed distributors to withdraw all existing stock from the Spanish market.
• Officials warn that undisclosed sildenafil can cause cardiovascular reactions such as heart attack, stroke and fatal arrhythmias.
• Labeling falsely promoted vitamins and minerals, misleading consumers about the product’s true composition.